Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
2.
J Am Med Inform Assoc ; 31(6): 1441-1444, 2024 May 20.
Article in English | MEDLINE | ID: mdl-38452298

ABSTRACT

OBJECTIVES: This article aims to examine how generative artificial intelligence (AI) can be adopted with the most value in health systems, in response to the Executive Order on AI. MATERIALS AND METHODS: We reviewed how technology has historically been deployed in healthcare, and evaluated recent examples of deployments of both traditional AI and generative AI (GenAI) with a lens on value. RESULTS: Traditional AI and GenAI are different technologies in terms of their capability and modes of current deployment, which have implications on value in health systems. DISCUSSION: Traditional AI when applied with a framework top-down can realize value in healthcare. GenAI in the short term when applied top-down has unclear value, but encouraging more bottom-up adoption has the potential to provide more benefit to health systems and patients. CONCLUSION: GenAI in healthcare can provide the most value for patients when health systems adapt culturally to grow with this new technology and its adoption patterns.


Subject(s)
Artificial Intelligence , Delivery of Health Care , Humans
3.
JAMA ; 329(23): 2038-2049, 2023 06 20.
Article in English | MEDLINE | ID: mdl-37338878

ABSTRACT

Importance: Use of oral vitamin K antagonists (VKAs) may place patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke caused by large vessel occlusion at increased risk of complications. Objective: To determine the association between recent use of a VKA and outcomes among patients selected to undergo EVT in clinical practice. Design, Setting, and Participants: Retrospective, observational cohort study based on the American Heart Association's Get With the Guidelines-Stroke Program between October 2015 and March 2020. From 594 participating hospitals in the US, 32 715 patients with acute ischemic stroke selected to undergo EVT within 6 hours of time last known to be well were included. Exposure: VKA use within the 7 days prior to hospital arrival. Main Outcome and Measures: The primary end point was symptomatic intracranial hemorrhage (sICH). Secondary end points included life-threatening systemic hemorrhage, another serious complication, any complications of reperfusion therapy, in-hospital mortality, and in-hospital mortality or discharge to hospice. Results: Of 32 715 patients (median age, 72 years; 50.7% female), 3087 (9.4%) had used a VKA (median international normalized ratio [INR], 1.5 [IQR, 1.2-1.9]) and 29 628 had not used a VKA prior to hospital presentation. Overall, prior VKA use was not significantly associated with an increased risk of sICH (211/3087 patients [6.8%] taking a VKA compared with 1904/29 628 patients [6.4%] not taking a VKA; adjusted odds ratio [OR], 1.12 [95% CI, 0.94-1.35]; adjusted risk difference, 0.69% [95% CI, -0.39% to 1.77%]). Among 830 patients taking a VKA with an INR greater than 1.7, sICH risk was significantly higher than in those not taking a VKA (8.3% vs 6.4%; adjusted OR, 1.88 [95% CI, 1.33-2.65]; adjusted risk difference, 4.03% [95% CI, 1.53%-6.53%]), while those with an INR of 1.7 or lower (n = 1585) had no significant difference in the risk of sICH (6.7% vs 6.4%; adjusted OR, 1.24 [95% CI, 0.87-1.76]; adjusted risk difference, 1.13% [95% CI, -0.79% to 3.04%]). Of 5 prespecified secondary end points, none showed a significant difference across VKA-exposed vs VKA-unexposed groups. Conclusions and Relevance: Among patients with acute ischemic stroke selected to receive EVT, VKA use within the preceding 7 days was not associated with a significantly increased risk of sICH overall. However, recent VKA use with a presenting INR greater than 1.7 was associated with a significantly increased risk of sICH compared with no use of anticoagulants.


Subject(s)
Brain Ischemia , Endovascular Procedures , Intracranial Hemorrhages , Ischemic Stroke , Thrombectomy , Vitamin K , Aged , Female , Humans , Male , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Brain Ischemia/drug therapy , Brain Ischemia/mortality , Brain Ischemia/surgery , Endovascular Procedures/adverse effects , Endovascular Procedures/methods , Endovascular Procedures/mortality , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/adverse effects , Fibrinolytic Agents/therapeutic use , Hemorrhage/chemically induced , Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/etiology , Ischemic Stroke/drug therapy , Ischemic Stroke/mortality , Ischemic Stroke/surgery , Retrospective Studies , Thrombectomy/adverse effects , Thrombectomy/methods , Thrombectomy/mortality , Treatment Outcome , Vitamin K/antagonists & inhibitors , Administration, Oral , Hospital Mortality , International Normalized Ratio
4.
Curr Atheroscler Rep ; 17(9): 51, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26194057

ABSTRACT

Heparin has long been a contested therapy in acute ischemic stroke (AIS). In current practice, heparin is considered on a case-by-case basis, but there is no consensus as to the appropriate timing of anticoagulation or for which ischemic stroke subtypes heparin may be beneficial. To provide better clarity on this issue, we review current research focusing on the use of heparin in AIS in each stroke subtype and subsequently make recommendations to provide readers with a systematic approach to managing complex stroke patients for which acute anticoagulation may be valuable. We conclude that there are certain subpopulations of ischemic stroke patients that may derive benefit from heparin when given acutely, including patients with symptomatic large artery stenosis >70 %, non-occlusive intraluminal thrombus, and in patients with high-risk cardiac conditions including left ventricular thrombus, left ventricular assist devices, and mechanical heart valves.


Subject(s)
Anticoagulants/therapeutic use , Heparin/therapeutic use , Stroke/drug therapy , Cerebral Hemorrhage/etiology , Clinical Protocols , Humans , Treatment Outcome
6.
Cerebrovasc Dis ; 39(5-6): 278-86, 2015.
Article in English | MEDLINE | ID: mdl-25871492

ABSTRACT

BACKGROUND AND AIMS: Systematic studies of superficial siderosis (SS) and convexity subarachnoid hemorrhage (cSAH) in patients with suspected cerebral amyloid angiopathy (CAA) without lobar intracerebral hemorrhage (ICH) are lacking. We sought to determine the potential anatomic correlation between SS/cSAH and transient focal neurological episodes (TFNE) and whether SS/cSAH is predictor of future cerebral hemorrhagic events in these patients. METHODS: We enrolled 90 consecutive patients with suspected CAA (due to the presence of strictly lobar microbleeds (CMBs) and/or SS/cSAH) but without the history of symptomatic lobar ICH who underwent brain MRI including T2*-weighted, diffusion-weighted imaging and fluid-attenuated inversion recovery sequences from an ongoing single center CAA cohort from 1998 to 2012. Evaluation of SS, cSAH and CMBs was performed. Medical records and follow-up information were obtained from prospective databases and medical charts. TFNE was defined according to published criteria and electroencephalogram reports were reviewed. RESULTS: Forty-one patients (46%) presented with SS and/or cSAH. The prevalence of TFNE was significantly higher in those with SS/cSAH (61 vs. 10%; p < 0.001) and anatomically correlated with the location of cSAH, but not SS. The majority of TFNE in patients with SS/cSAH presented with spreading sensory symptoms. Intermittent focal slowing on electroencephalogram was present in the same area as SS/cSAH in 6 patients, but no epileptiform activity was found in any patients. Among those with available clinical follow-up (76/90 patients, 84%), ten patients with SS/cSAH (29%, median time from the scan for all patients with SS/cSAH: 21 months) had a symptomatic cerebral bleeding event on follow up (average time to events: 34 months) compared with only 1 event (2.4%, 25 months from the scan) in patients without SS/​cSAH (time to event: 25 months) (p = 0.001). The location of hemorrhages on follow-up scan was not in the same location of previously noted SS/cSAH in 9 of 10 patients. Follow-up imaging was obtained in 9 of 17 patients with cSAH and showed evidence of SS in the same location as initial cSAH in all these 9 cases. CONCLUSIONS: SS/cSAH is common in patients with suspected CAA without lobar intracerebral hemorrhage and may have a significantly higher risk of future cerebral bleeding events, regardless of the severity of the baseline CMB burden. The findings further highlight a precise anatomical correlation between TFNE and cSAH, but not SS. Distinct from transient ischemic attack or seizure, the majority of TFNE caused by SS/cSAH appear to present with spreading sensory symptoms.


Subject(s)
Cerebral Amyloid Angiopathy/epidemiology , Ischemic Attack, Transient/epidemiology , Siderosis/epidemiology , Subarachnoid Hemorrhage/epidemiology , Adult , Aged , Aged, 80 and over , Cerebral Amyloid Angiopathy/complications , Cerebral Hemorrhage/complications , Female , Humans , Ischemic Attack, Transient/complications , Magnetic Resonance Imaging/adverse effects , Male , Middle Aged , Prevalence , Prospective Studies , Risk , Siderosis/complications , Subarachnoid Hemorrhage/complications
7.
Ann Neurol ; 75(1): 155-60, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24038455

ABSTRACT

Eight years after emigrating from Brazil, an otherwise healthy man developed rabies. An exposure prior to immigration was reported. Genetic analysis revealed a canine rabies virus variant found only in the patient's home country, and the patient had not traveled internationally since immigrating to the United States. We describe how epidemiological, phylogenetic, and viral sequencing data provided confirmation that rabies encephalomyelitis may present after a long, multiyear incubation period, a consideration that previously has been hypothesized without the ability to exclude a more recent exposure. Accordingly, rabies should be considered in the diagnosis of any acute encephalitis, myelitis, or encephalomyelitis.


Subject(s)
Emigrants and Immigrants , Infectious Disease Incubation Period , Phylogeny , Rabies/cerebrospinal fluid , Rabies/diagnosis , Adult , Animals , Brazil , Dogs , Humans , Male , Time Factors , United States
9.
J Neurophysiol ; 97(2): 1280-7, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17005620

ABSTRACT

P/Q-type voltage-dependent Ca(2+) channels (VDCCs) are highly expressed in the cerebellum, and mutations of these channels are associated with disrupted motor function. Several allelic variants of the alpha1A pore-forming subunit of P/Q-type VDCCs have been described, and mice homozygous for these mutations exhibit gait ataxia, as do alpha1A knockout mice. Here we report that heterozygous alpha1A mutants also have a motor phenotype. Mice heterozygous for the leaner and alpha1A knockout mutations exhibit impaired motor learning in the vestibulo-ocular reflex (VOR), suggesting that subtle disruption of P/Q Ca(2+) currents is sufficient to disrupt motor function. Basal VOR and optokinetic reflex performance were normal in the heterozygotes but severely impaired in the leaner and alpha1A knockout homozygotes.


Subject(s)
Calcium Channels, P-Type/genetics , Calcium Channels, P-Type/physiology , Calcium Channels, Q-Type/genetics , Calcium Channels, Q-Type/physiology , Gait Ataxia/genetics , Gait Ataxia/physiopathology , Animals , Heterozygote , Homozygote , Mice , Mice, Inbred C57BL , Mice, Knockout , Oculomotor Muscles/innervation , Oculomotor Muscles/physiopathology , Oculomotor Nerve/physiopathology , Phenotype , Psychomotor Performance/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...